Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

被引：24

作者：

Handunnetti, Sasanka M. ^{[1
,2
,3
]}

Anderson, Mary Ann ^{[1
,4
]}

Burbury, Kate ^{[1
,2
,3
]}

Hicks, Rodney J. ^{[1
,3
]}

Birbirsa, Besiat ^{[1
]}

Bressel, Mathias ^{[1
]}

Di Iulio, Juliana ^{[1
]}

Westerman, David Alan ^{[1
,2
,3
]}

Lade, Stephen ^{[5
]}

Agarwal, Rishu ^{[1
]}

Dawson, Mark A. ^{[1
,2
,3
]}

Dawson, Sarah-Jane ^{[1
,3
]}

Koldej, Rachel ^{[3
,6
]}

Ritchie, David ^{[1
,3
,7
,8
]}

Seymour, John F. ^{[1
,2
,3
]}

Roberts, Andrew W. ^{[1
,2
,3
,4
]}

Tam, Constantine S. ^{[1
,2
,3
,9
]}

机构：

[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[2] Royal Melbourne Hosp, Melbourne, Vic, Australia

[3] Univ Melbourne, Fac Med Dent & Hlth Sci, Parkville, Vic, Australia

[4] Walter & Eliza Hall Inst Med Res, Blood Cells & Blood Canc, Melbourne, Vic, Australia

[5] Peter MacCallum Canc Ctr, Dept Anat Pathol, Melbourne, Vic, Australia

[6] Royal Melbourne Hosp, ACRF Translat Res Lab, Melbourne, Vic, Australia

[7] Royal Melbourne Hosp, Parkville, Vic, Australia

[8] Univ Melbourne, Parkville, Vic, Australia

[9] St Vincents Hosp, Fitzroy, Vic, Australia

来源：

关键词：

D O I：

10.1182/blood-2019-126619

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

756

引用

页数：5